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SUMMARY
Metastasis, which commonly uses lymphatics, accounts for much of the mortality associated with cancer.
The vascular endothelial growth factor (VEGF)-C coreceptor, neuropilin-2 (Nrp2), modulates but is not nec-
essary for developmental lymphangiogenesis, and its significance for metastasis is unknown. An antibody
to Nrp2 that blocks VEGFC binding disrupts VEGFC-induced lymphatic endothelial cell migration, but not
proliferation, in part independently of VEGF receptor activation. It does not affect established lymphatics
in normal adult mice but reduces tumoral lymphangiogenesis and, importantly, functional lymphatics asso-
ciated with tumors. It also reduces metastasis to sentinel lymph nodes and distant organs, apparently by
delaying the departure of tumor cells from the primary tumor. Our results demonstrate that Nrp2, which
was originally identified as an axon-guidance receptor, is an attractive target for modulating metastasis.INTRODUCTION
Metastases are responsible for the majority (90%) of deaths
associated with solid tumors (Gupta and Massague, 2006). The
complex process of metastasis involves a series of distinct
steps, including intravasation of tumor cells into lymphatic or
blood vessels. Analysis of regional lymph nodes in many tumor
types suggests that the lymphatic vasculature is an important
route for the dissemination of human cancers. Furthermore, in al-
most all carcinomas, the presence of tumor cells in lymph nodes
is the most important adverse prognostic factor. Although it was
previously thought that such metastases exclusively involved
passage of malignant cells along pre-existing peritumoral lym-phatic vessels, recent experimental studies and clinicopatholog-
ical reports (reviewed in Achen et al., 2006; Achen and Stacker,
2006; Nathanson, 2003) suggest that lymphangiogenesis in-
duced by solid tumors can promote tumor spread. However,
the role of lymphatics in association with tumors is still the sub-
ject of significant debate. Regardless, numerous recent studies
suggest that targeting lymphatics and lymphangiogenesis may
be a useful therapeutic strategy to restrict cancer metastasis,
which would have a significant benefit for patients.
VEGFC, a member of the vascular endothelial growth factor
(VEGF) family, is one of the best-studied mediators of lymphatic
development. Overexpression of VEGFC in tumor cells has
been shown to promote tumor-associated lymphangiogenesis,SIGNIFICANCE
Tumor cell metastasis accounts for much of the mortality associated with cancer. Currently, there is no clinical therapeutic
strategy that specifically targets the development of metastasis. Modulation of the VEGFC axis by inhibition of ligand
(VEGFC) or receptor (VEGFR3) has shown promise in reducing the development of metastasis in preclinical models. We
have generated a monoclonal function-blocking antibody to neuropilin-2 (Nrp2), a VEGFC coreceptor. Here, we show
that anti-Nrp2 treatment inhibits the formation of functional lymphatics within tumors and inhibits the development of me-
tastasis, in part independently of VEGF receptor activation. These data imply that Nrp2 is an attractive target for modulating
metastasis.Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc. 331
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(reviewed in Stacker et al., 2002a, 2002b). VEGFC expression
has also been correlated with tumor-associated lymphangiogen-
esis and lymph node metastasis for a number of human cancers
(reviewed in Achen et al., 2006). In addition, blockade of VEGFC-
mediated signaling has been shown to suppress tumor lymphan-
giogenesis and lymph node metastases in mice (Chen et al.,
2005; He et al., 2002; Lin et al., 2005).
VEGFC is known to bind at least two receptor families, the
tyrosine kinase VEGF receptors and the neuropilin (Nrp) recep-
tors. VEGFC can bind VEGFR2 and VEGFR3, leading to recep-
tor activation and autophosphorylation, which, in turn, induces
angiogenesis and lymphangiogenesis (Ferrara et al., 2003).
VEGFC also binds to neuropilin-2 (Nrp2) (Favier et al., 2006;
Soker et al., 2002). Homozygous Nrp2 mutants show a reduc-
tion of small lymphatic vessels and capillaries prenatally (Yuan
et al., 2002). These genetic studies demonstrate that Nrp2
modulates, but is not necessary for, developmental lymphan-
giogenesis. This raises the intriguing possibility that Nrp2 may
be a modulator of tumor lymphangiogenesis and that blocking
Nrp2 function may reduce metastasis, which is yet to be ad-
dressed.
Nrp2 was initially identified as a semaphorin receptor and me-
diator of axon guidance (Chen et al., 1997). Interestingly, many
proteins that were originally discovered to be required for axon
guidance during nervous system development have also been
recently implicated in vascular system development (Carmeliet
and Tessier-Lavigne, 2005). These observations have primarily
been made for blood vessel development but are starting to ex-
tend to lymphatic vessel development as well (Yuan et al., 2002).
The Nrps are one such family of axon guidance molecules that
are implicated in both blood and lymphatic vessel development.
Nrps have short intracellular domains that are not known to have
any enzymatic or signaling activity. It has been proposed that
Nrps function to enhance VEGF receptor signaling by enhancing
ligand-VEGF receptor binding (Favier et al., 2006; Soker et al.,
2002). In addition, Sema3F, the semaphorin ligand of Nrp2,
has been shown to modulate endothelial cell behavior in vitro
and in vivo (Favier et al., 2006). However, recent reports have
suggested an alternate possibility that Nrps may function inde-
pendently of VEGF receptors or semaphorin function to modu-
late endothelial cell (EC) migration (Pan et al., 2007; Wang
et al., 2003).
To evaluate these mechanisms and to determine the role of
Nrp2 in modulating adult lymphangiogenesis and metastasis,
we generated a function-blocking antibody to Nrp2. Our in vitro
analysis with this antibody suggests that Nrp2 plays a role in
modulating lymphatic endothelial cell (LEC) migration and that
its function extends beyond its previously assigned role as an en-
hancer of VEGF receptor activation. In addition, we demonstrate
that blocking of Nrp2 leads to an inhibition of tumor lymphangio-
genesis in adult mice. We furthermore demonstrate that treat-
ment with anti-Nrp2 antibody results in a reduction of functional
lymphatics associated with tumors. It also causes a reduction in
metastasis to sentinel lymph node (SLN) and distant organs,
likely by causing a delay in the efflux of tumor cells from the
primary tumor. Thus, we provide strong evidence directly dem-
onstrating the role of Nrp2, an axon guidance receptor, in mod-
ulating metastasis.332 Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc.RESULTS
Generation of a Phage-Derived
Anti-Nrp2-Specific Antibody
To evaluate the role of Nrp2 in modulating VEGFC-mediated
functions, we generated a high-affinity, phage-derived mono-
clonal antibody (mAb) to Nrp2. The antibody was targeted to
the coagulation V/VII factor (b1-b2) domains of Nrp2 (Figure 1A),
which are required for VEGFC binding to Nrps (Karpanen et al.,
2006). This mAb bound with similar affinity to murine (Kd of 4.9
nM) and human (Kd of 5.3 nM) Nrp2 but did not bind Nrp1 (Fig-
ure 1B). We confirmed that the mAb bound exclusively to the
b1-b2 domains and did not bind to the CUB (a1-a2) domains
of human Nrp2, which are primarily responsible for semaphorin
Figure 1. Characterization of Anti-Nrp2B mAb
(A) Schematic representation of Sema- and VEGF-binding regions on Nrp2
relative to anti-Nrp2B epitope regions.
(B) ELISA assay demonstrating binding of anti-Nrp2B to hNrp2 ECD (filled
squares) and b1-b2 domains of hNrp2 (filled circles), but not hNrp1 ECD
(open squares) or the a1-a2 domains of hNrp2 (open circles).
(C) Blocking of VEGFC binding to Nrp2 by anti-Nrp2B.
(D) Blocking of VEGF binding to Nrp2 by anti-Nrp2B.
(E) Blocking of Sema3F binding to Nrp2-293 cells. No binding was observed
with alkaline phosphatase (AP) (top-left panel), but was seen with Sema3F
(top-right panel). This was not blocked by anti-Nrp2B (bottom-left panel), but
was blocked by Nrp2 ECD (bottom-right panel).
(F) Quantification of AP activity from cellular binding assay with Sema3F and
Sema3C.
*p < 0.05; error bars represent SEM. Scale bar, 100 mm.
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Nrp2B.
We then tested the ability of anti-Nrp2B to block binding
of VEGFC or VEGF (Gluzman-Poltorak et al., 2000) to Nrp2 in
both ELISA format and in cell-based binding assays. Anti-
Nrp2B strongly blocked the binding of both VEGFC (Figure 1C)
and VEGF (Figure 1D) to Nrp2 and HEK293 cells transfected
with full-length Nrp2 (Nrp2-293; data not shown) with a similar
IC50 (0.1 nM). However, anti-Nrp2
B was not able to block binding
of Sema3F or Sema3C (Chen et al., 1997) to Nrp2-293 cells (Fig-
ures 1E and 1F). These results are consistent with previous
observations that the a1-a2 domains are primarily responsible
for semaphorin binding and the b1-b2 domains for VEGF binding
(Figure 1A).
Anti-Nrp2B Blocks Selective VEGFC-Mediated
Functions In Vitro
We next examined the role of Nrp2 in VEGFC-mediated migra-
tion and proliferation—key cellular activities induced by VEGFC
(Joukov et al., 1997). LECs have been previously shown to be
Figure 2. Anti-Nrp2B Reduces VEGFC-
Induced Function In Vitro and In Vivo
(A) Representative images of stained LECsmigrat-
ing in response to 200 ng/ml of VEGFC in the pres-
ence or absence of 50 mg/ml of anti-Nrp2B or
VEGFR3 ECD.
(B) Quantification of LEC migration to 200 ng/ml
VEGFC. For each condition, n = 6.
(C) Quantification of LEC migration to 10 ng/ml
VEGF in the presence or absence of 50 mg/ml of
anti-Nrp2B or VEGFR3 ECD. For each condition,
n = 6.
(D) Representative images of LYVE-1-stained cor-
nea, illustrating the effects of intracorneal place-
ment of a 150 ng pellet of VEGFC (P) and systemic
treatment with anti-Nrp2B (10 mg/kg twice weekly)
or VEGFR3 ECD (25 mg/kg twice weekly). LYVE-1
staining has been pseudocolored red to facilitate
visualization.
(E) Quantification of the pixel counts from the cor-
neal micropocket assay described in (D).
*p < 0.05; error bars represent SEM. Scale bar,
600 mm for (A) and (D).
highly responsive to VEGFC (Makinen
et al., 2001b). Using a transwell system,
we evaluated human LEC migration to
VEGFC (Figures 2A and 2B). VEGFR3
extracellular domain protein (ECD), com-
prising the first three (ligand binding) Ig
domains of VEGFR3, was used as a posi-
tive control to block VEGFC-driven
migration in this and subsequent experi-
ments (Makinen et al., 2001a). Anti-
Nrp2B was able to significantly reduce
VEGFC-mediated LECmigration (Figures
2A and 2B; p = 0.004). The level of inhibi-
tion was lower than that seen with
VEGFR3 ECD, which completely in-
hibited VEGFC-mediated LEC migration (Figures 2A and 2B;
p = 0.002 versus anti-Nrp2B).
Because anti-Nrp2B also blocked VEGF binding to Nrp2, we
evaluated the role of Nrp2 in modulating VEGF-mediated LEC
migration (Makinen et al., 2001b). Anti-VEGF (B20.4.1) blocked
this migration (Pan et al., 2007), whereas anti-Nrp2B did not
have any effect (Figure 2C), possibly as a result of functional
redundancy with Nrp1 (see Figure S1 available online). This hy-
pothesis was confirmed by inhibiting Nrp1 function using anti-
Nrp1B (Pan et al., 2007; Figures S2A and S2B). The addition of
anti-Nrp2B to anti-Nrp1B did not result in any further inhibition
of migration (Figures S2A and S2B), indicating that Nrp2 does
not play a role in VEGF-mediated migration. Furthermore,
because Nrp1 has been shown to be able to bind VEGFC (Karpa-
nen et al., 2006), we also tested whether Nrp1 is necessary for
VEGFC-induced migration. Treatment with anti-Nrp1 mAbs
(Pan et al., 2007) did not result in any inhibition of VEGFC-
induced migration (Figure S2C).
We next investigated the effect of anti-Nrp2B on VEGFC-
induced LEC proliferation. Remarkably, anti-Nrp2B had no effectCancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc. 333
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block (Figure S2D), which is in agreement with the results of pre-
vious reports showing that Nrp2 siRNA failed to inhibit VEGFC-
induced proliferation in endothelial cells (Favier et al., 2006).
Thus, Nrp2 appears to be important for VEGFC-drivenmigration,
but not proliferation.
We also tested the ability of anti-Nrp2B to modulate sema-
phorin function. We used the hippocampal growth cone collapse
assay, which previously demonstrated that Nrp2 is required for
the Sema3C- and Sema3F-mediated retraction (Chen et al.,
1997). The addition of anti-Nrp2B did not have any effect on
the semaphorin-induced collapse, whereas the addition of re-
combinant Nrp2 ECD inhibited this collapse completely (Figures
S2E and S2F). This result is consistent with our previous obser-
vation that anti-Nrp2B does not interfere with Sema binding
to Nrp2. Thus, anti-Nrp2B acts to block specific aspects of
Nrp2 function, inhibiting a subset of VEGFC-mediated cellular re-
sponses but not those mediated by VEGF or Sema3F.
Anti-Nrp2B Blocks VEGFC-Mediated
Lymphangiogenesis In Vivo
Having observed a significant reduction in LEC migration by
blocking Nrp2 in vitro, we examined whether Nrp2 was required
for VEGFC function in vivo. We studied two well-characterized
VEGFC-mediated in vivo activities: adult lymphangiogenesis
and vascular permeability (Cao et al., 2004; Joukov et al.,
1998). To study lymphangiogenesis, we used the murine corneal
micropocket assay (Kubo et al., 2002), inwhich a pellet of VEGFC
induced robust lymphangiogenesis in the avascular cornea of an
adult mouse over the course of 14 days (Figure 2D; 12,000 pixels
with VEGFC treatment versus 2,284 pixels in control). Systemic
administration of VEGFR3 ECD almost completely blocked
VEGFC-induced lymphangiogenesis (2,671 pixels). Anti-Nrp2B
also blocked the corneal lymphangiogenic response equivalently
(3,281 pixels; p = 0.67 versus VEGFR3 ECD).
To evaluate vascular permeability, we used the Miles assay
(Brkovic and Sirois, 2007). Remarkably, treatment with anti-
Nrp2B had no effect on VEGFC-induced permeability, in contrast
to the block observed with VEGFR3 ECD treatment (p = 0.038;
Figure S3A), and demonstrated that, consistent with what we ob-
served in vitro, Nrp2 appeared to be important for selective
VEGFC-mediated functions in vivo.
Anti-Nrp2B Inhibits Nrp2/VEGF Receptor
Complex Formation
The finding that anti-Nrp2B interferes with VEGFC actions was
perhaps not surprising, because it blocks VEGFC binding to
Nrp2. However, the fact that it blocks only selective functions
both in vitro and in vivo was unexpected. One possible explana-
tion for this selective activity is that anti-Nrp2B may generally
inhibit LEC migration or adhesion. Anti-Nrp2B did not have any
effect on migration induced by VEGF (Figure 2C) or hepatocyte
growth factor (HGF) (Figure 3B), indicating no general disruption
to LEC migration. Furthermore, anti-Nrp2B did not have any
effect on LEC adhesion to extracellular matrix substrates fibro-
nectin or collagen (data not shown).
A second possibility is that the anti-Nrp2B mAb may cause
internalization of Nrp2. As Nrp2 forms a complex with VEGFR3,
even in the absence of ligand (Favier et al., 2006), this could334 Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc.result in cointernalization of VEGFR3, affecting specific
VEGFC-mediated functions. To address this possibility, we pre-
incubated LECs with anti-Nrp2B at 37C and then evaluated the
level of VEGF receptors and Nrp receptors on the cell surface by
FACS. No difference was observed between treatments, sug-
gesting that anti-Nrp2B did not cause significant internalization
of Nrp2, VEGFR2, or VEGFR3 (Figure 3A). Because VEGFC
can potentiate the interaction between Nrp2 and VEGF recep-
tors, we conducted similar internalization experiments in the
presence of 200 ng/ml of VEGFC. Again, no difference was ob-
served between treatments (Figure S3E).
Because Nrp2 has been proposed to augment VEGF receptor
signaling (Favier et al., 2006), we next studied the effect of anti-
Nrp2B on VEGFR2 and VEGFR3 activation, in which VEGFC
stimulation leads to receptor dimerization and autophosphoryla-
tion. VEGFR3 ECD completely blocked VEGFC-mediated
VEGFR2 (Figure S3B) and VEGFR3 (Figure 3C) phosphorylation.
Anti-Nrp2B treatment resulted in a reduction of VEGFR2 (Figure
S3B) and VEGFR3 (Figure 3C) activation, but to a lesser degree
than VEGFR3 ECD treatment. This observation raised the
possibility that the selective inhibitory activity of anti-Nrp2B
could be a result of differential requirements of VEGF receptor
activation for migration and proliferation. To address this
possibility, we evaluated the dose response of VEGFR2 and
VEGFR3 phosphorylation to VEGFC stimulation (Figure 3C
and Figure S3B). We consistently observed that the reduction
by anti-Nrp2B treatment of VEGFR2 phosphorylation stimulated
by 200 ng/ml of VEGFC was roughly equivalent to the VEGFR2
phosphorylation obtained by stimulating with 175 ng/ml or 150
ng/ml of VEGFC in the absence of antibody. This result was
also noted to be the case for VEGFR3. We then performed
a dose-response analysis of migration to VEGFC stimulation.
We reasoned that, if the reduction in VEGF receptor activation
alone was responsible for the reduced migration seen with anti-
Nrp2B treatment, then stimulation of LECs with 150 or 175 ng/
ml of VEGFC should have similar reduced degree of migration
as well. However, we did not see any reduction of LEC migra-
tion with 175 or 150 ng/ml of VEGFC (Figure 3D). A significant
reduction in migration was not observed until VEGFC levels
were reduced to 50 ng/ml. We therefore reasoned that the re-
duction in VEGF receptor activation induced by anti-Nrp2B
was, by itself, insufficient to reduce migration. We also evalu-
ated the effect of anti-Nrp2B on downstream signaling events
mediated by VEGF receptors. Treatment with anti-Nrp2B or
stimulation with 150 ng/ml of VEGFC did not significantly re-
duce activation of Erk1/2 or p38 MAPK (Figure S3D), which
modulate VEGF receptor-mediated proliferation and motility,
respectively. This result indicated that Nrp2 might regulate
LEC migration and lymphangiogenesis by a mechanism other
than enhancing VEGF receptor activation or downstream
signaling.
Finally, we tested the effect of anti-Nrp2B on Nrp2/VEGF
receptor complex formation. As reported elsewhere, Nrp2 can
be coimmunoprecipitated with VEGFR2 and VEGFR3 in the
presence or absence of VEGFC (Favier et al., 2006; Karpanen
et al., 2006), and this interaction was dramatically reduced by
anti-Nrp2B (Figure 3E and Figure S3C). This result suggests
that the Nrp2/VEGF receptor complex is important for specific
VEGFC-mediated functions. Furthermore, the role of Nrp2 is
Cancer Cell
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to ligand stimulation.
Nrp2 Is Expressed in Tumor-Associated Lymphatics
As reported elsewhere (Yuan et al., 2002), Nrp2 staining is pres-
ent in developing lymphatic vessels found in E12.5 mice
(Figure 4A). To determine whether Nrp2 plays a role in adult lym-
phatic biology, we evaluated the expression of Nrp2 in adult lym-
phatics. As described above, LECs in culture strongly express
Nrp2 (Figure S1). However, wewere unable to detect Nrp2 by im-
munohistochemistry (IHC) in LYVE-1-positive lymphatic vessels
of colon or lymph node in normal adult mice (Figures 4B and 4C),
confirmed by Nrp2 in situ hybridization (ISH; Figure S4C). In con-
trast, strong Nrp2 expression was observed in LYVE-1-positive
lymphatic vessels, within and around tumors and in lymph nodes
adjacent to tumors (Figure 4D). This was observedwith a number
of tumor lines, including the breast adenocarcinoma line (66c14)
(Aslakson and Miller, 1992), the rodent glioblastoma line (C6),
and human prostate carcinoma (PC3 line) (Figure 4E). This
Figure 3. Nrp2B Treatment Results in a
Reduction in VEGF Receptor Activation
and Inhibits Nrp2/VEGF Receptor Complex
Formation
(A) FACS analysis of Nrp2, VEGFR2, and VEGFR3
levels on the surface of LEC after treatment with
control antibody (10 mg/ml; green line) or anti-
Nrp2B (10 mg/ml) for 5 min (blue line), or 20 hr
(red line).
(B) Quantification of LEC migration to 20 ng/ml
HGF in the presence or absence of 50 mg/ml of
anti-Nrp2B or VEGFR3 ECD. For each condition,
n = 6.
(C) VEGFR3 phosphorylation level as assayed by
the VEGFR3 KIRA assay. pVEGFR3 levels in anti-
Nrp2B (10 mg/ml)-treated cells was significantly
different from the VEGFC stimulation at 200 ng/
ml and consistently lay between the phosphoryla-
tion level induced by 175 ng/ml and 150 ng/ml of
VEGFC. For each condition, n = 6.
(D) Quantification of LEC migration to VEGFC
(concentration as noted) in the presence or ab-
sence of VEGFR3 ECD (10 mg/ml). Significant re-
ductions in migration were noted at 50 ng/ml of
VEGFC or when blocked with VEGFR3 ECD.
(E) Immunoprecipitation with anti-VEGFR3. Cell
lysate or immunoprecipitation (IP) material was
probed with anti-Nrp2 or anti-VEGFR3 as indi-
cated.
*p < 0.05; error bars represent the SEM. Each ex-
periment was repeated a minimum of three times.
expression was confirmed by ISH in
a subset of tumor types (Figure S4B).
These tumor-associated lymphatic ves-
sels are likely a result of active lymphan-
giogenesis (Achen et al., 2006). To evalu-
ate Nrp2 expression in newly growing
vessels, we stained corneas from the cor-
nealmicropocket assay described above.
We saw Nrp2 expression in new lym-
phatics vessels (Figure 4F), with stronger
expression seen in the growing tip of the vessel. Thus, Nrp2 is
not expressed in quiescent adult lymphatics but is present during
lymphangiogenesis, in both development and adult tissues.
Anti-Nrp2B Reduces Lung Metastasis
in Multiple Tumor Models
One major approach to studying metastasis has been via inhibi-
tion of the VEGFC axis in orthotopic (Chen et al., 2005) or hetero-
topic subcutaneous (He et al., 2002; Krishnan et al., 2003; Lin
et al., 2005) tumor models. To determine whether blocking
Nrp2 function could also modulate the development of metasta-
sis, we tested the effects of anti-Nrp2B treatment on the forma-
tion of lung metastasis in two different tumor models—66c14
and C6 tumor models. We evaluated distant organ metastasis,
because it represents the end result of the metastatic cascade
and allows us to determine whether inhibition of Nrp2 has a
meaningful role in reducing metastasis. 66c14 is a murine mam-
mary carcinoma line derived from a spontaneous tumor; it ex-
presses VEGFC and metastasizes via the lymphatic system toCancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc. 335
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not affect the primary growth rate of the tumors (Figure 5A).
Because VEGFR3 ECD did reduce 66c14 primary tumor growth
rates (data not shown), it was excluded from any further analysis
Figure 4. Nrp2 Is Expressed Developmentally and in the Lymphatics
of Tumor-Bearing Mice
(A) Nrp2 staining (green) in E12.5 mouse embryo sections colocalizes with
Prox-1 (red) staining lymphatic endothelial cells. Additionally, Nrp2-stained
axons can be seen in the spinal cord (arrow), in the expected pattern acting
as a positive control for Nrp2 IHC. A higher magnification of the boxed area
is shown in the right panel.
(B and C) LYVE-1 staining (left column, red) labeling lymphatics, Nrp2 staining
(middle column, green), and the overlay (right column) in the (B) intestine and
(C) lymph node of normal adult mouse. Nrp2 signal does not colocalize with
LYVE-1-labeled lymphatics in either organ.
(D) In lymph nodes from tumor-bearing animals, Nrp2 signal does colocalize
with LYVE-1-positive lymphatic vessels lining the LN sinuses.
(E) Strong Nrp2 staining is also seen in lymphatic vessels within C6 tumors.
Boxed areas are shown at high magnification within insets.
(F) Nrp2 and LYVE-1 double staining in a cross-section of cornea from a cor-
neal micropocket assay. The specimen is oriented so that the VEGFC pellet
was placed above the upper border of the image. An LYVE-1-positive (red)
vessel (arrow) can be seen to express Nrp2 (green). Nrp2 can also be seen
in Descement’s membrane and in cells of the anterior corneal epithelium.
More Nrp2 staining is seen in the growing tip of the vessel. A higher magnifica-
tion of the boxed area is shown in the right panel and shows Nrp2 staining in
the growing vessel tip.
Scale bar, 200 mm for (A)–(E) (60 mm for inserts) and 100 mm for (F).336 Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc.of metastasis. A cohort of animals (n = 6) with similar sized
tumors from both arms were killed concurrently, and the lungs
were harvested and evaluated formetastasis. Anti-Nrp2B caused
a significant reduction in the average number of visually detected
metastatic nodules per lung, compared with control IgG-treated
animals (Figures 5B and 5C), from an average of 3.5 to 0.8
Figure 5. Anti-Nrp2B Treatment Results in a Reduction of Lung Me-
tastasis in the 66c14 Tumor Model
(A) Mean tumor volume graph of 66c14 tumor model study analyzed below.
(B) Quantification by visual inspection of the number of metastatic nodules per
lung in control and anti-Nrp2B-treated animals.
(C) Representative images of lungs from control (left) and anti-Nrp2B-treated
(right) animals. Lungs were inflated prior to fixation by right cardiac ventricular
perfusion. Nodules are highlighted in white to facilitate visualization.
(D and E) Three-dimensional renderings of representative micro-CT scanned
lungs demonstrating metastatic nodules (red) in control (D) and anti-Nrp2B-
treated (E) animals. The positions of the longitudinal section (top inset) and
the cross-section (bottom insert) are indicated by the black and red dotted
lines respectively.
(F) Quantification of the number of metastatic nodules per lung by micro-CT
analysis of the lungs.
(G) FACS analysis of Nrp2 levels on the surface of in vitro-cultured 66c14 tumor
cells.
(H) H&E staining of a lung nodule (arrow) demonstratingmetastatic tumor cells.
*p < 0.05; error bars represent SEM. Scale bar, 2mm for (C) and 400 mm for (H).
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parenchyma, we performed a micro-CT analysis (Li et al., 2006)
of the lungs. This analysis confirmed that anti-Nrp2B-treated
animals had a reduction in the number of lung metastasis, com-
pared with control-treated animals (Figures 5D, 5E, and 5F).
Micro-CT analysis was more sensitive, resulting in detection of
a larger absolute number of metastatic nodules in both groups.
Micro-CT also allowed us to determine the total metastatic
burden within the lung. Anti-Nrp2B treatment also resulted in a
reduction of total metastatic volume (0.74 cm3) in comparison
to control treatment (1.78 cm3).
FACS analysis indicated that Nrp2, but not VEGFR2 or
VEGFR3, was expressed on 66c14 tumor cells (Figure 5G and
Figure S5). This raised the possibility that treatment with anti-
Nrp2B was affecting tumor cell behavior directly to impact
metastasis. Anti-Nrp2B did not have any effect on tumor cell pro-
liferation, apoptosis, or migration in vitro (data not shown). How-
ever, to address the possibility that the reduction in metastasis
was due to effects of anti-Nrp2B on tumor cells, we also evalu-
ated the effect of anti-Nrp2B on subcutaneously transplanted
C6 tumor cells. These cells do not express Nrp2 on their surface
to an appreciable degree (Figure 6E), but they do express
VEGFC and are thought to metastasize to the lung via the lym-
phatic system (Bernstein and Woodard, 1995). Additionally,
they have been engineered to express b-galactosidase to facili-
tate detection of tumor cells.
Anti-Nrp2B treatment did not affect the primary growth rate of
these tumors (Figure 6A). Additionally, VEGFR3 ECD did not dra-
matically reduce primary tumor growth rate in this tumor model,
allowing for comparisons of the antimetastatic effects of VEGFR3
ECD and anti-Nrp2B. Again, a cohort of animals (n = 10) with
similar sized tumors from all treatment arms were killed, and
the lungs were assessed. Treatment with either anti-Nrp2B or
VEGFR3 ECD caused a reduction in the average number of visu-
ally detected metastatic nodules per lung (Figures 6B and 6C).
The reduction noted with anti-Nrp2B was comparable to that
seen with VEGFR3 ECD. Micro-CT analysis of the lungs con-
firmed these findings (Figure 6D). Nodules were confirmed to
be metastatic lesions by histology in both tumor models (Figures
5H and 6F). Additionally, general necropsy did not reveal nodules
on the surface of other organs in either tumor model.
Blocking Nrp2 Function Results in a Reduction
of Tumor Lymphatics
To understand the mechanism by which anti-Nrp2B treatment
reduced metastasis, we evaluated the primary tumors (n = 5 ani-
malsper group for both studies). For 66c14orC6 tumors, thegen-
eral architectureof tumor tissuewascomparablebetweencontrol
and anti-Nrp2B-treated tumors by hematoxylin and eosin (H&E)
staining (data not shown). In addition, Ki67 IHC and TUNEL stain-
ingdidnot demonstrate anydifferences inproliferationor apopto-
sis in the tumors (data not shown), consistent with the similar
growth ratesobserved.Becausemetastasesare thought tooccur
via blood or lymphatic vessels, we also used PECAM-1 and
LYVE-1 IHC, respectively, to evaluate these vessels within tu-
mors. PECAM-1 staining revealed no morphological or quantita-
tivedifferencesbetweencontrol andanti-Nrp2B-treated tumors in
the 66c14 study and between control, anti-Nrp2B-treated, and
VEGFR3ECD-treated tumors in theC6 study (Figures 7A and7C).In contrast, LYVE-1 staining revealed a dramatic reduction of
lymphatic vessel density in anti-Nrp2B-treated tumors, com-
pared with control tumors, in both 66c14 and C6 studies (Figures
7B and 7C). Furthermore, the level of reduction was quantita-
tively similar to that seen with VEGFR3 ECD treatment (Fig-
ure 7C). Anti-Nrp2B treatment also led to differences in lymphatic
morphology, compared with control tissue (Figure 7C, middle
and lower panels). The lymphatic structures in control tumors
formed complex networks with large luminal vessels lined by in-
tact LECs (Ji and Kato, 2003). However, the lymphatic structures
in anti-Nrp2B-treated tumors were rare single vessels with small
lumens. More commonly, small regions of multiple isolated LECs
were noted in anti-Nrp2B-treated tumors. Despite the similar
Figure 6. Anti-Nrp2B Treatment Results in a Reduction of Lung Me-
tastasis in the C6 Tumor Model
(A) Mean tumor volume graph of C6 tumor model study analyzed below.
(B) Quantification by visual inspection of the number of metastatic nodules per
lung in control, VEGFR3 ECD-treated, and anti-Nrp2B-treated animals.
(C) Representative images of lungs from control (left), VEGFR3 ECD-treated
(middle), and anti-Nrp2B-treated (right) animals. Nodules are highlighted in
white to facilitate visualization.
(D) Three-dimensional renderings of representative micro-CT scanned lungs
demonstrating metastatic nodules (red) in control (left), VEGFR3 ECD-treated
(middle) and Anti-Nrp2B-treated (right) animals.
(E) FACS analysis of Nrp2 levels on the surface of in vitro-cultured C6 tumor
cells.
(F) H&E staining of a lung nodule (arrow) demonstrating metastatic tumor cells.
*p < 0.05; error bars represent SEM. Scale bar 2 mm for (C) and 400 mm for (F).Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc. 337
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a Reduction of Tumor Lymphatic Vessels
(A and B) Quantification of vascular vessel density
(A) by PECAM-1 IHC and lymphatic vessel density
(B) by LYVE-1 IHC in 66c14 tumors treated with
control antibody or anti-Nrp2B. Vessel density
was determined from 6 representative images
from each of 6 tumors per group, evaluated for
mean pixel number by ImageJ.
(C) Representative mages of PECAM-1 stained
vessels (top row) and LYVE-1 stained lymphatic
vessels (middle row) and LYVE-1/TUNEL double
stained (bottom row) in C6 tumors treated with
control antibody (left column), VEGFR3 ECD (mid-
dle column) or Anti-Nrp2B (right column). While
TUNEL positive apoptotic cells (red) are present
in control tissue (arrows), they are not associated
with intact lymphatic vessels (green). In contrast,
many LYVE-1/TUNEL double stained cells (arrow
heads) are noted in the disrupted and fragmenting
lymphatics of VEGFR3 ECD-treated tumors.
Clusters of single lymphatic endothelial cells with
rare apoptotic lymphatic cells are noted in Anti-
Nrp2B-treated tumors. Quantification of vascular
(top graph) and lymphatic (middle graph) vessel
density and number of LYVE-1/TUNEL double
positive cells (bottom graph) are to the right of
these images. Images and quantification primarily
limited to 1mm from the edge of the tumormargin.
(D) LYVE-1 stained tumors from Anti-Nrp2B-
treated animals (bottom panels) harvested at day
4 (Harvest 1) and day 11 (Harvest 2) demonstrate
disruption of lymphatic vessels in comparison to
control-treated animals (top panels). The harvest
dates relative to growth curves are shown to the
left.
*p < 0.05; error bars represent SEM. Scale bar,
200 mm for (C) (top, middle row) and 50 mm for
(C) (bottom row) and (D).reduction in lymphatic vascular density, the morphology of
lymphatic vessels was different in VEGFR3 ECD-treated tumors,
where sparse networks comprised small vessels lined by frag-
menting LECs. Only rarely were intact lymphatic vessels ob-
served. IHCwith podoplanin, another marker of lymphatics, con-
firmed these findings (data not shown). We also conducted
LYVE-1 and TUNEL double staining on these tissues to deter-
mine whether the number of apoptotic lymphatics cells was
increased in response to treatment (Figure 7C). We observed
a significant increase in the number of apoptotic lymphatic cells
in VEGFR3 ECD-treated tumors, in comparison to control tu-
mors. Interestingly, there was no significant increase in the num-
ber of apoptotic lymphatic cells in tumors treatedwith anti-Nrp2B
(Figure 7C). We propose that the reduction of metastasis seen
with anti-Nrp2B treatment is due to the reduction of tumor-asso-
ciated lymphatics, as has been hypothesized in studies blocking
VEGFC function (He et al., 2002).
Next, we sought to determine whether anti-Nrp2B acts by
inhibiting tumor lymphangiogenesis or by disrupting existing
mature tumor lymphatics. To address this issue, we evaluated
tumors that were harvested from control and anti-Nrp2B-treated338 Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc.tumors at early and late time points in the study. If at early time
points, anti-Nrp2B-treated tumors had intact lymphatic net-
works, the likely mechanism for anti-Nrp2B action would be
disruption of existing lymphatics. However, if at early time points,
these tumors had abnormal lymphatics, the likely mechanism
would be an inhibition of tumor lymphangiogenesis. We com-
pared lymphatic development in treated and control tumors at
both time points. Day 4 (after initiation of anti-Nrp2B treatment)
was selected as the early time point, because it was the first
time point when control-treated primary tumors had mature
lymphatic vessels. We observed similar disrupted lymphatic
morphologies in early and late time points in anti-Nrp2B-treated
tissue, suggesting that anti-Nrp2B disrupts the formation of lym-
phatic structures (Figure 7D).
Finally, we evaluated the effects of anti-Nrp2B treatment on the
normal lymphatics in adult mice. Analysis of intestinal, cutane-
ous, pancreatic, and lymph node lymphatics by LYVE-1 IHC of
mice treated for five weeks with anti-Nrp2B revealed no qualita-
tive or quantitative differences between treated and untreated
mice (Figure S6). This suggests that blocking of Nrp2 does not
affect maintenance of quiescent adult lymphatics.
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in Functional Lymphatics
Our results demonstrate that anti-Nrp2B treatment reduced the
lymphatic vessel density within tumors. We next tested the
effects of anti-Nrp2B treatment on functional tumor lymphatics,
because these were most likely to be involved in metastasis.
We employed the commonly used technique of intradermal
lymphangiography with Evans Blue (Isaka et al., 2004), because
it can be easily extracted from tissue and quantified. Tumor lym-
phatics likely sprout from dermal lymphatics and are, therefore,
continuous with them. Because the dermal lymphatics drain
deeply (toward the larger lymphatic vessels in the center of the
body), the dye injected intradermally, which enters the skin lym-
phatics, can, paradoxically, travel to the tumor on its way to the
sentinel lymph node (Padera et al., 2002). Lymphangiography
was performed on control and anti-Nrp2B-treated mice bearing
C6 and 66c14 tumors between 500 and 600 mm3 (before the on-
set of tumor necrosis). As Evans Blue dye was transported into
the tumor primarily by lymphatic vessels, we quantified the total
tumor Evans Blue content as a measure of functional lymphatics
within the tumors. Nrp2B treatment resulted in a dramatic reduc-
tion in Evans Blue levels within tumors (0.55 OD600/g) (Figures 8A
and 8B; n = 4). We did not anticipate any nonspecific leakage,
because the dye was injected into normal skin, where Evans
Blue could not cross blood vessel walls. To confirm this, we
also tested the blood from these animals for Evans Blue, which
was not present at detectable levels. This result strongly sug-
gests that anti-Nrp2B treatment results in a reduction of func-
tional lymphatics within tumors.
Figure 8. Anti-Nrp2B Treatment Results in a Reduction of Functional
Tumor Lymphatic Vessels and Leads to a Delay in Metastasis to the
Primary Lymph Node
(A and B) Anti-Nrp2B treatment results in a reduction of Evans Blue within C6
(A) (p = 0.035) and 66c14 (B) (p = 0.005) tumors, indicating a reduction in func-
tional lymphatics within these treated tumors.
(C) Percentage of animals with SLNs containing b-gal expressing C6 tumor
cells at various time points after tumor implantation in the ears of control
(black) and anti-Nrp2B-treated (red) mice. Anti-Nrp2B treatment results in a de-
lay of arrival of cells at the SLN (p = 0.006). n = 7 animals per treatment condi-
tion per time point.
*p < 0.05; error bars represent SEM.Blocking Nrp2 Function Results in a Delay
of Metastasis via the Lymphatic System
We predicted that blocking Nrp2 function should result in a delay
of one of the early steps in the metastatic cascade—arrival of
tumor cells at the sentinel lymph node (SLN). The SLN is the first
tissue that metastasizing cells encounter after exiting the tumor
and entering the lymphatic system. Thus, we performed a subcu-
taneous transplantation of C6 tumor cells into the ear, because it
has a well-defined lymphatic drainage pattern and a single SLN
(Hoshida et al., 2006). Animals were removed from control and
anti-Nrp2B treatment arms at various time points, and SLNs
were evaluated for the presence of metastatic cells in a highly
sensitive manner (as few as 10 tumor cells could be detected;
data not shown) by assessing b-galactosidase activity. Tumor
cells were identified in the SLNs of control animals as early at 3
days after implantation (Figure 8C). Micrometastasis was initially
identified in anti-Nrp2B-treated SLNs at 6 days postimplantation.
As predicted, analysis of the remainder of the time course re-
vealed a significant delay in the development of tumor cell-pos-
itive SLNs in anti-Nrp2B-treated animals. Furthermore, a reduc-
tion in formation of positive SLNs in addition to this observed
delay cannot be ruled out.
DISCUSSION
A key early event in metastasis involves the egress of tumor cells
from the primary tumor, often via the lymphatic system. VEGFC
is a keymodulator of lymphangiogenesis andmetastasis inmany
tumor models, and inhibition of the VEGFC axis is considered
a promising strategy for inhibiting the development of metasta-
sis. To date, Nrp2, a coreceptor for VEGFC, has not been a target
for inhibitingmetastasis. Our studies support an important role of
Nrp2 in tumor lymphangiogenesis andmetastasis, only in part by
modulating VEGFR3 signaling. In addition, we demonstrate that
treating with anti-Nrp2B results in a reduction of functional lym-
phatics, impacting the early steps of metastasis to SLNs.
Nrp2 Regulates Selective VEGFC Functions,
in Part through a Mechanism Independent
of VEGF Receptor Activation
Induction of migration and proliferation are two key cellular func-
tions of VEGFC (Joukov et al., 1997). Our finding that blocking
Nrp2 with anti-Nrp2B blocked LECmigration but not proliferation
(Figures 2 and 3) was therefore surprising. A similar selectivity,
recently reported with Nrp2 siRNA knockdown experiments,
was attributed to experimental technical limitations (Favier
et al., 2006). We also demonstrated Nrp2’s functional selectivity
in vivo, because anti-Nrp2B treatment resulted in a reduction of
VEGFC-driven lymphangiogenesis but not vascular permeability
(Figures 2 and 3). This insensitivity of permeability to treatment
with anti-Nrp2B may reflect the minimal biological relevance of
the Nrp2-VEGFR2 interaction (permeability is primarily mediated
by VEGFR2), differential sensitivity of lymphangiogenesis and
vascular permeability to Nrp2 inhibition, or the fact that lymphan-
giogenesis requires LEC migration, whereas permeability may
not. Nevertheless, these observations suggest that inhibition
with anti-Nrp2B does not simply disrupt VEGFC signaling. Block-
ing of Nrp2 did result in a modest reduction in VEGF receptor
phosphorylation (Figure 3), supporting a mechanism wherebyCancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc. 339
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tent with previous reports (Favier et al., 2006). However, because
this lower level of receptor phosphorylation was still able to max-
imally drive LEC migration, we determined that the observed in
vitro inhibition of migration could not be exclusively attributed
to this reduction in VEGF receptor phosphorylation (Figure 3).
This suggested an additional role for Nrp2 in this process.
We therefore investigated other mechanisms by which block-
ing of Nrp2 may selectively affect migration, such as modulation
of adhesion or motility. Anti-Nrp2B treatment did not have any ef-
fect on LEC-mediated adhesion (data not shown) or non-VEGFC-
induced migration (Figures 2 and 3), indicating that this was un-
likely. Sema3F, another ligand of Nrp2, may modulate LEC or
EC migration, acting as a chemorepellent (Favier et al., 2006).
However, our antibody did not alter the binding of Sema3F to
Nrp2 (Figure 1) or the functional effects of Sema3F (Figure S2).
Thus, it is unlikely that the reduction in VEGFC-inducedmigration
by anti-Nrp2B is a result of modulation of Sema3F function.
We also evaluated the effect of anti-Nrp2B on the formation
of the Nrp2/VEGF receptor complex. Nrp2 forms a complex
with VEGFR2 and VEGFR3 in the absence of ligand (Favier
et al., 2006; Karpanen et al., 2006), and anti-Nrp2B inhibits the
formation of these complexes. This observation, coupled with
the fact that Nrp2 is significant for more than just augmentation
of VEGF receptor function, supports a model in which Nrp2
specifically modulatesmigration as part of the receptor complex,
potentially by binding additional molecular mediators. A similar
mechanism of action has recently been proposed for the role
of Nrp1 in modulating endothelial cell motility in response to
VEGF (Pan et al., 2007). Neuropilin interacting protein (NIP, also
known as GIPC), a PDZ domain-containing protein that interacts
with the short intracellular domain of Nrps, is one such potential
mediator of this process (Cai and Reed, 1999). It interacts with
integrins and may modulate the signaling of many different re-
ceptor systems via its interaction with GAIP, an RGS (regulators
of G protein signaling) protein (El Mourabit et al., 2002).
Nrp2 Regulates Adult Lymphangiogenesis but Is Not
Required for the Maintenance of Preformed Lymphatics
Analysis of Nrp2 KOmice demonstrates that Nrp2 is a modulator
of developmental lymphangiogenesis, presumably via its role as
a VEGFC coreceptor (Yuan et al., 2002). However, these mutant
mice form functional lymphatics after birth, suggesting that either
there is compensation by another molecular mediator or the de-
fect represents a delay rather than inhibition of lymphatic growth.
The role of Nrp2 in maintaining mature lymphatics and modulat-
ing adult lymphangiogenesis is not known. Our expression anal-
ysis (Figure 4 and Figure S4) does not support a role of Nrp2 in
maintaining adult lymphatics. Interestingly, Nrp2 is expressed
in tumoral lymphatics and within LNs adjacent to tumors, sug-
gesting that Nrp2 may play a role in activated or growing lym-
phatics. Although anti-Nrp2B inhibited adult lymphangiogenesis
in the corneal assay, it did not have any effect on quiescent intes-
tinal, cutaneous, pancreatic, or lymph node lymphatics, confirm-
ing that Nrp2 does not play a role in maintenance of normal lym-
phatics (Figure S6). Therefore, anti-Nrp2B treatment is unlikely
to result in compromise of the normal lymphatic system leading
to complications seen with use of VEGFR3 ECD, such as lymph-
edema (Makinen et al., 2001a).340 Cancer Cell 13, 331–342, April 2008 ª2008 Elsevier Inc.Nrp2 Inhibition Leads to a Reduction in Functional
Tumor Lymphatics and in Metastasis
Both orthotopic and subcutaneous tumor models have been
extensively used to study the metastatic process, importantly,
allowing modulation of early steps in the complex metastatic
process (intravasation) and evaluation of the end result (distant
organ metastasis). For lymphatic metastasis, subcutaneous
models have the advantage of access to rich lymphatic beds
and flexibility of tumor placement to allow evaluation of specific
aspects of metastasis (SLN metastasis; He et al., 2002), and
orthotopic models have the advantage of native microenviron-
ment. Inhibition of the VEGFC axis, most often by the use of
VEGFR3 ECD, is a commonly used strategy for reducing metas-
tasis in both orthotopic (Chen et al., 2005) and heterotopic sub-
cutaneous (He et al., 2002; Krishnan et al., 2003; Lin et al., 2005)
settings. VEGFCmay facilitate metastasis potentially by initiating
lymphangiogenesis, thereby increasing the surface area of tu-
mor cells in contact with LECs (Alitalo and Carmeliet, 2002).
Given the inhibitory effect of anti-Nrp2B on VEGFC-induced lym-
phangiogenesis, we next investigated the effects of blocking
Nrp2 on metastasis. To minimize confounding variables and
selectively evaluate the effect of anti-Nrp2B on metastasis, we
chose models in which blocking of Nrp2 does not affect primary
tumor growth and harvested all animals at the same time point
in the study. In both 66c14 and C6 tumor models, anti-Nrp2B
treatment resulted in a significant reduction of metastatic lung
nodules (Figures 5 and 6). Again, anti-Nrp2B treatment resulted
in an equivalent block of metastasis, compared with VEGFR3
ECD, which completely blocks VEGFC signaling.
Our histologic analysis indicated that anti-Nrp2B did not
directly affect tumor cells (data not shown). Thus, we evaluated
the two potential metastatic routes available to tumor cells:
blood vessels and lymphatics (Figure 7). Treatment with anti-
Nrp2B had no effect on blood vessels but, as hypothesized on
the basis of our corneal micropocket data, did reduce the density
of lymphatics equivalent to that seen with VEGFR3 ECD treat-
ment. However, these two treatments differed in themorphology
and apoptotic rate of the resulting lymphatic vessels (Figure 7),
further supporting a model in which Nrp2 does not simply act
to augment VEGF receptor activation but alsomodulates VEGFC
biology. Our results also demonstrate that, for the experimental
paradigms tested, anti-Nrp2B acts to inhibit lymphangiogenesis
(Figure 7). However, we cannot rule out that anti-Nrp2B also dis-
rupts more established lymphatic vessels within tumors.
Because it was possible that anti-Nrp2B reduced total lym-
phatic density while sparing functional vessels (which may have
different sensitivity to anti-Nrp2B), we evaluated the effects of
blocking Nrp2 on the formation of functional lymphatic vessels.
Anti-Nrp2B reduced the formation of functional vessels, thereby
more directly linking the effects on tumor lymphatics with the
observed reduction in metastasis.
Finally, to confirm the consequence of reducing functional lym-
phatics, we evaluated the effects of anti-Nrp2B on metastasis to
the SLN. The SLN is the first tissue that tumor cells encounter af-
ter departing from the tumor via the lymphatics andmetastasis to
theSLN represents oneof the earliest steps in themetastatic cas-
cade (Stracke and Liotta, 1992). As predicted, anti-Nrp2B treat-
ment resulted in a delay of the development of SLN micrometa-
stasis, consistent with the idea that fewer cells were effluxing
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that VEGFC increases metastasis by inducing lymphatic hyper-
plasia and increased delivery of cancer cells to lymph nodes
(Hoshida et al., 2006). Thus, the weight of evidence points to
a mechanism by which blocking of Nrp2 leads to a reduction in
functional tumor lymphatics, preventing tumor cells from initiat-
ing the metastatic process by exiting from the primary tumor
mass.
EXPERIMENTAL PROCEDURES
Cell Culture and In Vitro Assays
Human dermal LECs and human umbilical vein endothelial cells (HUVECs)
were purchased from Cambrex and cultured in EGM-2 medium (Cambrex).
C6 LacZ cells were purchased from ATCC. 66C14 were a kind gift from
F. Miller. Tumor cells were cultured in DMEM (GIBCO) supplemented with
10% FBS. All cells were maintained at 37C in a 5% CO2, 95% humidity incu-
bator. Cell migration, proliferation, adhesion, and internalization (FACS) assays
were performed as described elsewhere (Pan et al., 2007 and the Supplemen-
tal Data).
Animal Studies
All studies were conducted in accordance with the Guide for the Care and Use
of Laboratory Animals, published by the NIH (NIH Publication 85-23, revised
1985). An Institutional Animal Care and Use Committee (IACUC) approved
all animal protocols. Murine corneal micropocket assay and skin vessel
permeability assay were performed as described elsewhere (Pan et al., 2007
and the Supplemental Data).
Tumor Models
66C14 (2 3 105 cells in 10 ml PBS) and C6 (2 3 106 tumor cells in 100 ml PBS)
were injected into anesthetizedmice as noted in the Supplemental Data.When
tumors reach an average size of 80–120 mm3, mice were sorted, to give nearly
identical group mean tumor sizes, and were treated with isotype control anti-
ragweed antibody (10 mg/kg), anti-Nrp2B (10 mg/kg) or VEGFR3 ECD 25 mg/
kg i.p. twice weekly until study termination. Evaluation of tumor growth and
metastasis and histologic evaluation was performed as noted in the Supple-
mental Data.
For details on other experimental procedures, see the Supplemental Data.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
seven supplemental figures and can be found with this article online at
http://www.cancercell.org/cgi/content/full/13/4/331/DC1/.
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